GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Atreca Inc (OTCPK:BCEL) » Definitions » Free Cash Flow

Atreca (Atreca) Free Cash Flow : $-65.39 Mil (TTM As of Sep. 2023)


View and export this data going back to 2019. Start your Free Trial

What is Atreca Free Cash Flow?

Atreca's total free cash flow for the months ended in Sep. 2023 was $-17.28 Mil. Its total free cash flow for the trailing twelve months (TTM) ended in Sep. 2023 was $-65.39 Mil.

Atreca's Free Cash Flow per Share for the months ended in Sep. 2023 was $-0.44. Its free cash flow per share for the trailing twelve months (TTM) ended in Sep. 2023 was $-1.67.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was 18.60% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was 32.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Free Cash Flow Growth Rate using Free Cash Flow per Share data.

During the past 6 years, Atreca's highest 3-Year average Free Cash Flow per Share Growth Rate was 42.70% per year. The lowest was 18.60% per year. And the median was 38.80% per year.


Atreca Free Cash Flow Historical Data

The historical data trend for Atreca's Free Cash Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Atreca Free Cash Flow Chart

Atreca Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Free Cash Flow
Get a 7-Day Free Trial -36.46 -61.99 -71.70 -96.01 -81.61

Atreca Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Free Cash Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -16.60 -15.58 -14.52 -18.01 -17.28

Atreca Free Cash Flow Calculation

Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company.

Atreca's Free Cash Flow for the fiscal year that ended in Dec. 2022 is calculated as

Free Cash Flow (A: Dec. 2022 )=Cash Flow from Operations+Capital Expenditure
=-80.721+-0.885
=-81.61

Atreca's Free Cash Flow for the quarter that ended in Sep. 2023 is calculated as

Free Cash Flow (Q: Sep. 2023 )=Cash Flow from Operations+Capital Expenditure
=-17.216+-0.061
=-17.28

Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-65.39 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Atreca  (OTCPK:BCEL) Free Cash Flow Explanation

Free Cash Flow is very close to Warren Buffett's definition of Owner's Earnings, except that in Warren Buffett's Owner's Earnings, the spending for Property, Plant, and Equipment is only for maintenance (replacement), while in the Free Cash Flow calculation, the cost of new Property, Plant, and Equipment due to business expansion is also deducted. There, Free Cash Flow is more conservative than Owner's Earnings.

In Don Yacktman's calculation of forward rate of return, he uses Free Cash Flow for the calculation. Yacktman explained the forward rate of return concept in detail in his interview with GuruFocus. Yacktman defines forward rate of return as the normalized free cash flow yield plus real growth plus inflation.

This is what Yacktman said in his March 2012 interview - when the S&P 500 was at 1400:

If the business is stable, this calculation is fairly straightforward. For instance, on the S&P 500 we would normalize earnings. We would then calculate what percentage of those earnings are not reinvested in the underlying businesses and are therefore free. Historically, for the S&P 500, this has been just under 50% of earnings. Currently, we expect the S&P to earn about 70 on a normalized basis, a number which is far below reported earnings due to our adjusting for record high profit margins. $70 X ½ / 1400 gives you a normalized free cash flow yield of approximately 2.5%.

The historical real growth rate of the S&P 500 (companies) is about 1.5%. Assuming an inflation rate of 2.5%, the forward rate of return on an investment in the S&P 500 is about 6.5% today (2.5% free cash flow yield plus 1.5% real growth plus 2.5% inflation).

For the growth part of the Forward Rate of Return calculation, GuruFocus uses the 5-year average growth rate of EBITDA per share as the growth rate, and the growth rate is always capped at 20%. For the Free Cash Flow we use per share data averaged over seven years. The reason we use seven years is because research shows that seven years is the length of the typical business cycle.

Therefore, as of Sep23, Atreca's Forward Rate of Return (Yacktman) % is

Forward Rate of Return (Yacktman) % (Sep23)=Normalized Free Cash Flow/Price+5-Year EBITDA Growth Rate
=0/0.261+0
=0.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Free Cash Flow within a report period can be affected by management's decisions of capital spending. Therefore, it is important to look at long term when it comes to Free Cash Flow.


Atreca Free Cash Flow Related Terms

Thank you for viewing the detailed overview of Atreca's Free Cash Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Atreca (Atreca) Business Description

Traded in Other Exchanges
Address
835 Industrial Road, Suite 400, San Carlos, CA, USA, 94070
Atreca Inc is a biopharmaceutical company utilizing its differentiated platform to discover and develop novel antibody-based immunotherapeutics to treat a range of solid tumor types. It has single segment business of therapeutic drug discovery and development. The company's product candidate, ATRC-101, is a monoclonal antibody in preclinical development with a novel mechanism of action and target derived from an antibody identified using its discovery platform.
Executives
Felix Baker other: Former 10% Owner BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014
Baker Bros. Advisors Lp other: Former 10% Owner 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Baker Bros. Advisors (gp) Llc other: Former 10% Owner 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Julian Baker other: Former 10% Owner BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014
Roger Richard Ruiz officer: VP of Finance C/O ATRECA, INC., 835 INDUSTRIAL ROAD, SUITE 400, SAN CARLOS CA 94070
Stephen E Gould officer: Chief Scientific Officer C/O ATRECA, INC., 835 INDUSTRIAL ROAD, SUITE 400, SAN CARLOS CA 94070
Herb Cross officer: Chief Financial Officer 3061 ZANKER RD, SAN JOSE CA 95134
Tito Serafini director, officer: Chief Strategy Officer C/O ATRECA, INC., 500 SAGINAW DRIVE, REDWOOD CITY CA 94063
Phillips Courtney officer: General Counsel & Secretary ATRECA INC., 500 SAGINAW DRIVE, REDWOOD CITY CA 94063
Philippe C Bishop officer: Chief Medical Officer C/O ATRECA, INC., 835 INDUSTRIAL ROAD, SUITE 400, SAN CARLOS CA 94070
John A Orwin director, officer: President & CEO C/O RELYPSA, INC., 700 SAGINAW DR., REDWOOD CITY CA 94063
Stacey Ma director C/O ATRECA, INC., 835 INDUSTRIAL RD., SUITE 400, SAN CARLOS CA 94070
Stephen R Brady director C/O IMMUNE DESIGN CORP., 1616 EASTLAKE AVE. E, SUITE 310, SEATTLE WA 98102
Norman Michael Greenberg officer: Chief Scientific Officer 500 SAGINAW DRIVE, REDWOOD CITY CA 94063
William Hewitt Robinson director 500 SAGINAW DRIVE, REDWOOD CITY CA 94063

Atreca (Atreca) Headlines

From GuruFocus

BAKER BROS. ADVISORS LP Reduces Stake in Atreca Inc

By GuruFocus Research 10-24-2023

Atreca Announces Corporate Reorganization to Extend Cash Runway

By GuruFocusNews GuruFocusNews 07-01-2022

Atreca to Present at Upcoming Investor Conferences

By GuruFocusNews GuruFocusNews 07-08-2022

Atreca Appoints Stephen Gould, Ph.D. as Chief Scientific Officer

By GuruFocusNews GuruFocusNews 07-06-2022

Atreca Appoints Stephen Gould, Ph.D. as Chief Scientific Officer

By GuruFocusNews GuruFocusNews 06-26-2022

Atreca Announces Corporate Reorganization to Extend Cash Runway

By GuruFocusNews GuruFocusNews 06-11-2022

Atreca Appoints Philippe Bishop, MD as Chief Medical Officer

By Stock market mentor Stock market mentor 01-09-2023